文献速递泌尿生殖腹部MR

前列腺癌放疗前MRI对生化复发预后因素的影响

Prognostic factors of biochemical recurrence and impact of pre-treatment MRI for prostate cancer radiotherapy.
PubMed 文献 · Br J Radiol · 2025-01-01

本研究回顾性分析2014—2024年接受放疗的前列腺癌患者,1480例中499例(33.7%)放疗前接受了诊断性MRI。中位随访44个月,多因素分析显示病灶直径≥20 mm是生化复发的独立预后因素(HR=3.49,95%CI 1.25-9.76,P=0.017),且仅在高危CAPRA评分6-10分患者中显著。

要点

  • 放疗前MRI病灶直径≥20 mm是前列腺癌生化复发的独立预后因素(HR=3.49)。
  • 病灶≥20 mm的预后意义仅限于CAPRA 6-10分高危患者(占21%),P<0.001。
  • CAPRA评分与病灶直径无相关性(P=0.4),两者提供独立信息。

核心结论

  • 放疗前MRI病灶直径≥20 mm为生化复发的独立预后因素,尤其在高危CAPRA评分6-10分患者中;对这些病灶进行放疗剂量递增能否改善临床结局尚待明确。

研究设计与样本

  • 机构数据库回顾性分析,2014—2024年接受放疗的前列腺癌患者1480例,其中499例(33.7%)有放疗前诊断性MRI;49.5%接受低剂量率近距离放疗,29.8%接受外照射放疗联合高剂量率近距离放疗推量,20.7%仅接受外照射放疗;中位随访44个月(IQR 23-66)。

诊断标准与关键数值

  • MRI患者中404例(81%)为PI-RADS 4-5分,其中35%病灶≥15 mm、20%病灶≥20 mm;单因素分析病灶≥15 mm(P=0.026)和≥20 mm(P<0.001)及CAPRA评分(P<0.001)均显著;多因素分析仅病灶≥20 mm显著(HR=3.49,95%CI 1.25-9.76,P=0.017),≥15 mm不显著;按CAPRA分层仅高危(6-10分,占21%)中病灶≥20 mm显著(P<0.001)。

临床应用与阅片要点

  • 放疗前评估前列腺癌时,应在报告中明确测量并记录最大病灶直径,≥20 mm提示生化复发风险升高,尤其在高危CAPRA评分6-10分患者中。

局限性

  • 原文为机构数据库回顾性分析。
  • 原文结论指出对这些病灶进行放疗剂量递增能否改善临床结局尚待明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: We conducted an analysis of the prognostic implications of MRI findings prior to radiotherapy in patients diagnosed with prostate cancer.

METHODS: Patients from our institutional database who were treated with radiotherapy between 2014-2024 were searched for diagnostic MRI. The prognostic significance of PI-RADS score, index-lesion diameter, and Cancer of the Prostate Risk Assessment (CAPRA) score on biochemical recurrence was analysed.

RESULTS: Of the 1480 patients, 499 (33.7%) underwent a diagnostic pre-treatment MRI; 49.5% were treated with low-dose brachytherapy, 29.8% with external beam radiation therapy (EBRT) plus a high-dose rate brachytherapy boost, and 20.7% with EBRT alone. Among the patients who underwent MRI, 404 (81%) had PI-RADS 4-5, including 35% with lesions ≥15 mm and 20% with lesions ≥20 mm. The median follow-up period was 44 months (IQR:23-66). Among the 78 patients who subsequently experienced biochemical recurrence, 16 underwent a diagnostic MRI prior to treatment. CAPRA score did not correlate with lesion diameter (P = 0.4). In univariate analysis, lesions ≥15 mm (P = 0.026) and ≥20 mm (P < 0.001) were significant predictors, as was CAPRA score (P < 0.001). In multivariate analyses, lesion size ≥20 mm (hazard ratio [HR], 3.49; 95%CI:1.25-9.76, P = 0.017) but not ≥15 mm significantly predicted recurrence. Stratified by CAPRA, only in high-risk cancers (score 6-10, 21% of patients) was a lesion ≥20 mm a significant predictor (P < 0.001).

CONCLUSIONS: We determined that a lesion on MRI with a diameter of ≥20 mm was an independent prognostic factor for biochemical recurrence, particularly in high-risk cancers. Whether the radiation dose-escalation of these lesions can improve clinical outcomes must be determined.

ADVANCES IN KNOWLEDGE: We found that a prostate lesion on MRI with a diameter ≥20 mm was associated with poorer outcomes following radiotherapy.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Margolese N, Dahan J, Olivié DAR, et al. Prognostic factors of biochemical recurrence and impact of pre-treatment MRI for prostate cancer radiotherapy. Br J Radiol. 2025. PMID: 40455006. doi:10.1093/bjr/tqaf122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。